Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nanomix Corporation
The US government is helping Sonica develop ADAM, a patch monitor that tracks the user's breathing patterns and other physiologic signals to detect SARS-CoV-2 infections.
The US government’s Biomedical Advanced Research and Development Authority has awarded Nanomix up to $570,000 to develop a SARS-CoV-2 test for its portable, rapid Nanomix eLab analyzer.
The theory that smaller is better--as it is has been in the computer industry--is now driving enthusiasm for nanotechnology, a term that refers to the process of manipulating materials at atomic scale. New players are crowding under this hot rubric, including many working at not nearly so small a scale. Drug discovery methods are among the most compelling near-term nano-applications, but start-ups face challenges like those met by micro-scale pioneers Affymetrix and Caliper. Firms must show they can physically create systems they describe, and that teeny discovery methods actually matter for bench scientists. Business models in this emerging sector reflect the difficulties of harnessing novel science in ways that will satisfy drugmakers who've become extra-tough customers under pressure to deliver commercial results in a shifting, financially depressed market. Some start-ups are working on a fee-for-service basis, on specific projects that address customers' immediate needs. Others are deliberately doing development work on their own, gathering data to attract partnerships that may prove all the more rewarding because of their measured starts.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Boston Therapeutics, Inc.
- Nanomix, Inc.